Union Bancaire Privee UBP SA Has $471,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Union Bancaire Privee UBP SA trimmed its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 55.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,622 shares of the medical research company's stock after selling 8,180 shares during the quarter. Union Bancaire Privee UBP SA's holdings in Edwards Lifesciences were worth $471,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in EW. Brighton Jones LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $266,000. Empowered Funds LLC raised its stake in Edwards Lifesciences by 6.2% in the fourth quarter. Empowered Funds LLC now owns 25,533 shares of the medical research company's stock valued at $1,890,000 after buying an additional 1,501 shares during the period. Focus Financial Network Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $206,000. Certuity LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $232,000. Finally, Van ECK Associates Corp increased its holdings in shares of Edwards Lifesciences by 35.0% during the 4th quarter. Van ECK Associates Corp now owns 171,102 shares of the medical research company's stock worth $12,666,000 after acquiring an additional 44,338 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on EW. Canaccord Genuity Group raised their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a report on Friday, April 25th. Citigroup reissued a "buy" rating and issued a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Finally, Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of "Hold" and an average target price of $80.20.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $0.77 during trading hours on Friday, reaching $75.12. 2,635,771 shares of the stock were exchanged, compared to its average volume of 5,226,474. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a market cap of $44.06 billion, a P/E ratio of 10.78, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The stock has a 50 day moving average of $74.54 and a two-hundred day moving average of $72.92.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $0.66 EPS. Equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,153,526.69. This represents a 27.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the sale, the vice president now directly owns 47,206 shares in the company, valued at approximately $3,295,450.86. The trade was a 16.75% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,948 shares of company stock valued at $3,122,845. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.